Entering text into the input field will update the search result below

Medgenics FY14 results

  • Medgenics (MDGN +0.1%) FY14 results: Revenues: $0; R&D Expense: $8.6M (+17.8%); SG&A: $10.7M (+1.9%); Operating Loss: ($18.9M) (-6.2%); Net Loss: ($18.4M) (-7.6%); Loss Per Share: ($1.00) (+5.7%); Quick Assets: $33.3M (+48.7%).
  • No guidance given.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
GNMX--
Aevi Genomic Medicine, LLC
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.